Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
76 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Amyloidosis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Amyloidosis - Pipeline Review, H2 2014', provides an overview of the Amyloidosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Amyloidosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyloidosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Amyloidosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Amyloidosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Amyloidosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Amyloidosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Amyloidosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Amyloidosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Amyloidosis Overview 7 Therapeutics Development 8 Pipeline Products for Amyloidosis - Overview 8 Pipeline Products for Amyloidosis - Comparative Analysis 9 Amyloidosis - Therapeutics under Development by Companies 10 Amyloidosis - Therapeutics under Investigation by Universities/Institutes 11 Amyloidosis - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Amyloidosis - Products under Development by Companies 15 Amyloidosis - Products under Investigation by Universities/Institutes 16 Amyloidosis - Companies Involved in Therapeutics Development 17 GlaxoSmithKline plc 17 Celgene Corporation 18 Onyx Pharmaceuticals, Inc. 19 Bellus Health Inc. 20 ProteoTech, Inc. 21 Auven Therapeutics Management L.L.L.P 22 NeuroPhage Pharmaceuticals, Inc. 23 SOM Biotech SL 24 Amyloidosis - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Combination Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 eprodisate disodium - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 SOM-0226 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 pomalidomide - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 carfilzomib - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 PTI-110 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 GSK-2315698 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 GSK-2398852 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 GSK-2315698 + GSK-2398852 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 NPT-005 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Small Molecule for AL Amyloidosis - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Amyloidosis - Recent Pipeline Updates 52 Amyloidosis - Dormant Projects 63 Amyloidosis - Product Development Milestones 64 Featured News & Press Releases 64 May 27, 2014: Auven Therapeutics and Bellus Health Announce Completion of Enrollment in the Phase III Confirmatory Study of Kiacta for the Treatment of AA Amyloidosis 64 May 07, 2014: Auven Therapeutics and BELLUS Health Announce Engagement of Financial Advisor to Explore Sale of KIACTA, an Experimental Drug in Phase III Development for the Treatment of AA Amyloidosis 64 Apr 28, 2014: Tekmira's Partner Presents New Clinical Data for LNP-Enabled Patisiran 65 Apr 23, 2014: Prothena's NEOD001 Demonstrates Encouraging Cardiac Biomarker Responses in Ongoing Phase 1 Study in Patients With Immunoglobulin Light Chain Amyloidosis 66 Mar 18, 2014: Prothena Announces Clinical Data to be Presented at the International Symposium on Amyloidosis 68 Jan 09, 2014: BELLUS Health provides update on KIACTA Phase III orphan drug study 68 Dec 16, 2013: Alnylam Initiates Phase II Clinical Trial with ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic Targeting Transthyretin in Development for the Treatment of TTR-Mediated Amyloidosis 69 Nov 25, 2013: Alnylam Earns $7 Million Milestone Payment from Genzyme for Phase II Success with Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin for the Treatment of TTR-Mediated Amyloidosis 70 Nov 11, 2013: Alnylam Receives Fast Track Designation for Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin for the Treatment of TTR-Mediated Amyloidosis 71 Nov 10, 2013: Alnylam Reports Positive Phase II Data for Patisiran, an RNAi Therapeutic Targeting Transthyretin for the Treatment of TTR-Mediated Amyloidosis, and Initiates Phase III Trial 72 Appendix 75 Methodology 75 Coverage 75 Secondary Research 75 Primary Research 75 Expert Panel Validation 75 Contact Us 76 Disclaimer 76
List of Tables Number of Products under Development for Amyloidosis, H2 2014 8 Number of Products under Development for Amyloidosis - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Number of Products under Investigation by Universities/Institutes, H2 2014 11 Comparative Analysis by Late Stage Development, H2 2014 12 Comparative Analysis by Clinical Stage Development, H2 2014 13 Comparative Analysis by Early Stage Development, H2 2014 14 Products under Development by Companies, H2 2014 15 Products under Investigation by Universities/Institutes, H2 2014 16 Amyloidosis - Pipeline by GlaxoSmithKline plc, H2 2014 17 Amyloidosis - Pipeline by Celgene Corporation, H2 2014 18 Amyloidosis - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 19 Amyloidosis - Pipeline by Bellus Health Inc., H2 2014 20 Amyloidosis - Pipeline by ProteoTech, Inc., H2 2014 21 Amyloidosis - Pipeline by Auven Therapeutics Management L.L.L.P, H2 2014 22 Amyloidosis - Pipeline by NeuroPhage Pharmaceuticals, Inc., H2 2014 23 Amyloidosis - Pipeline by SOM Biotech SL, H2 2014 24 Assessment by Monotherapy Products, H2 2014 25 Assessment by Combination Products, H2 2014 26 Number of Products by Stage and Target, H2 2014 28 Number of Products by Stage and Mechanism of Action, H2 2014 30 Number of Products by Stage and Route of Administration, H2 2014 32 Number of Products by Stage and Molecule Type, H2 2014 34 Amyloidosis Therapeutics - Recent Pipeline Updates, H2 2014 52 Amyloidosis - Dormant Projects, H2 2014 63
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
